Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGJ398 (Infigratinib) in FGFR-altered tumors
NCT02160041Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of infigratinib in solid tumor, hematologic malignancy, sponsored by Novartis. Started Jul 2014; status: terminated.
02
Drugs
infigratinib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT02160041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160041.